A M Manadan

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy
    Augustine M Manadan
    Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    J Rheumatol 30:1227-30. 2003
  2. ncbi Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade
    Augustine M Manadan
    Section of Rheumatology, John H Stroger Hospital of Cook County, Chicago, IL, USA
    Am J Ther 15:53-8. 2008
  3. ncbi Etanercept therapy in patients with a positive tuberculin skin test
    A M Manadan
    John H Stroger Hospital of Cook County Hospital, Chicago, USA
    Clin Exp Rheumatol 25:743-5. 2007
  4. ncbi New therapeutic approaches for spondyloarthritis
    Augustine M Manadan
    Hospital of Cook County and Rush University Medical Center, Chicago, Illinois, USA
    Curr Opin Rheumatol 19:259-64. 2007
  5. ncbi The treatment of psoriatic arthritis
    Augustine M Manadan
    Rush University Medical Center and John H Stroger Jr Hospital of Cook County, Chicago, Illinois 60612, USA
    Am J Ther 13:72-9. 2006
  6. ncbi Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis
    Augustine M Manadan
    Section of Rheumatology, Rush University Medical Center, Chicago, IL 60612, USA
    Semin Arthritis Rheum 34:683-8. 2005
  7. ncbi Daily needle aspiration versus surgical lavage for the treatment of bacterial septic arthritis in adults
    Augustine M Manadan
    Section of Rheumatology, Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Am J Ther 11:412-5. 2004
  8. ncbi Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections
    Rohit Aggarwal
    Department of Rheumatology, Rush University Medical Center, Chicago, IL 60612, USA
    J Rheumatol 36:914-7. 2009
  9. ncbi Pseudo-septic hip arthritis as the presenting symptom of ankylosing spondylitis: a case series and review of the literature
    Tanisha Mathur
    Rush University Medical Center and John H Stroger, Jr Hospital of Cook County, Chigago, IL, USA
    Clin Exp Rheumatol 28:416-8. 2010
  10. ncbi Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor
    Aparna K Mohan
    Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA
    Clin Infect Dis 39:295-9. 2004

Collaborators

Detail Information

Publications10

  1. ncbi The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy
    Augustine M Manadan
    Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    J Rheumatol 30:1227-30. 2003
    ..To characterize the frequency of thrombotic thrombocytopenic purpura (TTP) among patients with systemic lupus erythematosus (SLE) undergoing kidney biopsy...
  2. ncbi Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade
    Augustine M Manadan
    Section of Rheumatology, John H Stroger Hospital of Cook County, Chicago, IL, USA
    Am J Ther 15:53-8. 2008
    ..We review the data supporting the use of these agents, rituximab and abatacept...
  3. ncbi Etanercept therapy in patients with a positive tuberculin skin test
    A M Manadan
    John H Stroger Hospital of Cook County Hospital, Chicago, USA
    Clin Exp Rheumatol 25:743-5. 2007
    ..In this study, we attempted to evaluate the frequency of latent TB reactivation among patients treated with etanercept...
  4. ncbi New therapeutic approaches for spondyloarthritis
    Augustine M Manadan
    Hospital of Cook County and Rush University Medical Center, Chicago, Illinois, USA
    Curr Opin Rheumatol 19:259-64. 2007
    ..We critically review recent radiographic data suggesting that tumor necrosis factor alpha inhibition may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the disease course...
  5. ncbi The treatment of psoriatic arthritis
    Augustine M Manadan
    Rush University Medical Center and John H Stroger Jr Hospital of Cook County, Chicago, Illinois 60612, USA
    Am J Ther 13:72-9. 2006
    ..The tumor necrosis factor alpha (TNF-alpha) antagonists represent the most recent major advance in the clinical management of PsA...
  6. ncbi Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis
    Augustine M Manadan
    Section of Rheumatology, Rush University Medical Center, Chicago, IL 60612, USA
    Semin Arthritis Rheum 34:683-8. 2005
    ..To describe the association between thrombotic thrombocytopenic purpura (TTP) and systemic sclerosis (SSc) and the methods to distinguish TTP from scleroderma renal crisis (SRC)...
  7. ncbi Daily needle aspiration versus surgical lavage for the treatment of bacterial septic arthritis in adults
    Augustine M Manadan
    Section of Rheumatology, Rush Medical College, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Am J Ther 11:412-5. 2004
    ....
  8. ncbi Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections
    Rohit Aggarwal
    Department of Rheumatology, Rush University Medical Center, Chicago, IL 60612, USA
    J Rheumatol 36:914-7. 2009
    ..We evaluated the risk of developing active TB among PPD-positive patients treated with etanercept...
  9. ncbi Pseudo-septic hip arthritis as the presenting symptom of ankylosing spondylitis: a case series and review of the literature
    Tanisha Mathur
    Rush University Medical Center and John H Stroger, Jr Hospital of Cook County, Chigago, IL, USA
    Clin Exp Rheumatol 28:416-8. 2010
    ..In this study, we evaluated the frequency of severe hip arthritis mimicking septic arthritis as initial presenting symptom of AS...
  10. ncbi Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor
    Aparna K Mohan
    Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA
    Clin Infect Dis 39:295-9. 2004
    ..It is unclear whether etanercept therapy increases the risk of TB beyond the elevated TB rates already documented for patients with RA...